Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PARSIPPANY, N.J., April 03, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on Tuesday, April 4, 2017, in New York.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
